These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 11920210)

  • 21. Acute myeloid leukemia as a second malignancy: report of 9 pediatric patients in a single institution in Argentina.
    Felice MS; Zubizarreta PA; Chantada GL; Alfaro E; Cygler AM; Gallego M; Rossi J; Sackmann-Muriel F
    Med Pediatr Oncol; 1998 Mar; 30(3):160-4. PubMed ID: 9434824
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976-1993 and on 5098 unselected cases reported in the literature 1974-2001.
    Mauritzson N; Albin M; Rylander L; Billström R; Ahlgren T; Mikoczy Z; Björk J; Strömberg U; Nilsson PG; Mitelman F; Hagmar L; Johansson B
    Leukemia; 2002 Dec; 16(12):2366-78. PubMed ID: 12454741
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcome of patients who develop acute leukemia or myelodysplasia as a second malignancy after solid tumors treated surgically or with strategies that include chemotherapy and/or radiation.
    Abdelhameed A; Pond GR; Mitsakakis N; Brandwein J; Chun K; Gupta V; Kamel-Reid S; Lipton JH; Minden MD; Schimmer A; Schuh A; Yee K; Messner HA
    Cancer; 2008 Apr; 112(7):1513-21. PubMed ID: 18286528
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.
    Harrison CN; Gregory W; Hudson GV; Devereux S; Goldstone AH; Hancock B; Winfield D; MacMillan AK; Hoskin P; Newland AC; Milligan D; Linch DC
    Br J Cancer; 1999 Oct; 81(3):476-83. PubMed ID: 10507773
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Secondary acute myeloid leukaemia: results of conventional treatments. Experience of GIMEMA trials.
    Pagano L; Pulsoni A; Vignetti M; Tosti ME; Falcucci P; Fazi P; Fianchi L; Levis A; Bosi A; Angelucci E; Bregni M; Gabbas A; Peta A; Coser P; Ricciuti F; Morselli M; Caira M; Foà R; Amadori S; Mandelli F; Leone G;
    Ann Oncol; 2005 Feb; 16(2):228-33. PubMed ID: 15668275
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease.
    Tebbi CK; London WB; Friedman D; Villaluna D; De Alarcon PA; Constine LS; Mendenhall NP; Sposto R; Chauvenet A; Schwartz CL
    J Clin Oncol; 2007 Feb; 25(5):493-500. PubMed ID: 17290056
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Myelodysplastic Syndromes and Acute Myeloid Leukemia After Radiotherapy for Prostate Cancer: A Population-Based Study.
    Wang R; Zeidan AM; Yu JB; Soulos PR; Davidoff AJ; Gore SD; Huntington SF; Gross CP; Ma X
    Prostate; 2017 Apr; 77(5):437-445. PubMed ID: 27868212
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer.
    Le Deley MC; Suzan F; Cutuli B; Delaloge S; Shamsaldin A; Linassier C; Clisant S; de Vathaire F; Fenaux P; Hill C
    J Clin Oncol; 2007 Jan; 25(3):292-300. PubMed ID: 17159192
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group.
    Josting A; Wiedenmann S; Franklin J; May M; Sieber M; Wolf J; Engert A; Diehl V;
    J Clin Oncol; 2003 Sep; 21(18):3440-6. PubMed ID: 12668650
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapy-related acute myeloid leukaemia and myelodysplastic syndrome in Victoria, Australia 2003-2014.
    Ong DM; Farrugia H; Wei A
    Intern Med J; 2018 Jul; 48(7):822-829. PubMed ID: 29236346
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Why is there so much therapy-related AML and MDS and so little therapy-related CML?
    Gale RP; Hlatky L; Sachs RK; Radivoyevitch T
    Leuk Res; 2014 Oct; 38(10):1162-4. PubMed ID: 25175829
    [No Abstract]   [Full Text] [Related]  

  • 32. Leukemia incidence following primary breast carcinoma treatment.
    Kaplan HG; Malmgren JA; Atwood M
    Cancer; 2004 Oct; 101(7):1529-36. PubMed ID: 15378478
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incidence, clinical and biological characteristics and outcome of secondary acute lymphoblastic leukemia after solid organ or hematologic malignancy.
    Kelleher N; Gallardo D; González-Campos J; Hernández-Rivas JM; Montesinos P; Sarrá J; Gil C; Barba P; Guàrdia R; Brunet S; Bernal T; Martínez MP; Abella E; Bermúdez A; Sánchez-Delgado M; Antònia C; Gayoso J; Calbacho M; Ribera JM;
    Leuk Lymphoma; 2016; 57(1):86-91. PubMed ID: 25860236
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Leukemia as a second malignancy.
    Uppin MS; Paul TR; Rajappa S; Gayathri K; Jacob R; Uppin SG
    Indian J Pathol Microbiol; 2007 Jul; 50(3):644-7. PubMed ID: 17883171
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk of myelodysplastic syndrome and acute myeloid leukemia post radiation treatment for breast cancer: a population-based study.
    Kaplan H; Malmgren J; De Roos AJ
    Breast Cancer Res Treat; 2013 Feb; 137(3):863-7. PubMed ID: 23274844
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Secondary hematopoietic malignancies in survivors of childhood cancer: an analysis of 111 cases from the Surveillance, Epidemiology, and End Result-9 registry.
    Rihani R; Bazzeh F; Faqih N; Sultan I
    Cancer; 2010 Sep; 116(18):4385-94. PubMed ID: 20549819
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Second malignant neoplasms after treatment of childhood acute lymphoblastic leukemia.
    Schmiegelow K; Levinsen MF; Attarbaschi A; Baruchel A; Devidas M; Escherich G; Gibson B; Heydrich C; Horibe K; Ishida Y; Liang DC; Locatelli F; Michel G; Pieters R; Piette C; Pui CH; Raimondi S; Silverman L; Stanulla M; Stark B; Winick N; Valsecchi MG
    J Clin Oncol; 2013 Jul; 31(19):2469-76. PubMed ID: 23690411
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incidence and characterization of secondary myelodysplastic syndromes following autologous transplantation.
    Del Cañizo Mf; Amigo Mf; Hernández JM; Sanz G; Núñez R; Carreras E; Alegre A; Cuesta B; Mataix R
    Haematologica; 2000 Apr; 85(4):403-9. PubMed ID: 10756367
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapy-related myeloid leukemia after treatment for epithelial ovarian carcinoma: an epidemiological analysis.
    Vay A; Kumar S; Seward S; Semaan A; Schiffer CA; Munkarah AR; Morris RT
    Gynecol Oncol; 2011 Dec; 123(3):456-60. PubMed ID: 21855120
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High risk of therapy-related leukemia after BEAM chemotherapy and autologous stem cell transplantation for previously treated lymphomas is mainly related to primary chemotherapy and not to the BEAM-transplantation procedure.
    Pedersen-Bjergaard J; Pedersen M; Myhre J; Geisler C
    Leukemia; 1997 Oct; 11(10):1654-60. PubMed ID: 9324285
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.